China Biologic Products Appoints Director of Research and Development
September 09 2009 - 8:00AM
PR Newswire (US)
TAI'AN, China, Sept. 9 /PRNewswire-Asia-FirstCall/ -- China
Biologic Products, Inc. (OTC:CBPO) (BULLETIN BOARD: CBPO) ("China
Biologic," or the "Company"), one of the leading plasma-based
pharmaceutical companies in the People's Republic of China ("PRC"),
operating through its indirect majority-owned subsidiaries,
Shandong Taibang Biological Products Co. Ltd. ("Taibang") and
Chongqing Dalin Biologic Technologies Co., Ltd. ("Dalin") and its
equity investment in Xi'an Huitian Blood Products Co., Ltd.
("Huitian"), today announced that the Company has appointed Dr.
Vincent Yi-Wu Xie to be the Company's Director of Research and
Development, effective September 1, 2009, to oversee the
development of new biologic products covering processes, analytical
methods and indications. Dr. Xie is a veteran in the
biopharmaceutical industry and has published several papers and
articles related to the field of plasma-based research. He holds a
number of patents related to his biopharmaceutical research,
including research on plasma-derived hyperimmune globulins and
alpha-1 proteinase inhibitor, and has received the Guangzhou City
Science and Technology Award in connection with his work
"Preparation of Equine Antibodies against Avian Influenza." Prior
to joining China Biologic, Dr. Xie served from 2007 to 2009 as the
General Manager of Research and Development at New a-IKOR Limited,
a Hong Kong-based biopharmaceutical company, and from 2002 to 2007,
as the Director of Research & Development at Advantek Serum
Laboratories Limited, a Hong Kong plasma-based biopharmaceutical
company. Dr. Xie has also conducted postdoctoral research in
various departments in the University of Hong Kong and the Chinese
University of Hong Kong. "We are very pleased to have Dr. Xie join
our research team," commented Mr. Chao Ming Zhao, CEO of China
Biologic Products. "He brings years of research experience and
managerial expertise related to the biopharmaceutical industry to
China Biologic Products. We expect that his presence on our team
will serve to strengthen our research and development efforts as
part of our strategy to bring new higher margin products to
market." About China Biologic Products, Inc. China Biologic
Products, Inc. (the "Company"), through its indirect majority-owned
subsidiaries, Shandong Taibang Biological Products Co. Ltd. and
Chongqing Dalin Biologic Technologies Co., Ltd, and its equity
investment in Xi'an Huitian Blood Products Co., Ltd., is currently
the largest non-state-owned plasma-based biopharmaceutical company
in China. The Company is a fully integrated biologic products
company with plasma collection, production and manufacturing,
research and development, and commercial operations. The Company's
plasma-based biopharmaceutical products are irreplaceable during
medical emergencies, and are used for the prevention and treatment
of various diseases. It sells its products to hospitals and other
healthcare facilities in China. Safe Harbor Statement This release
may contain certain "forward-looking statements" relating to the
business of China Biologic Products, Inc. and its subsidiary
companies. All statements, other than statements of historical fact
included herein are "forward-looking statements," including
statements regarding: the impact of the appointment of Mr. Xie as
the Company's new Director of Research; the ability of the Company
to achieve its commercial objectives; the business strategy, plans
and objectives of the Company and its subsidiaries, including the
possibility that Mr. Xie's presence will advance the Company's
strategy to bring new higher margin products to market; and any
other statements of non-historical information. These
forward-looking statements are often identified by the use of
forward-looking terminology such as "believes," "expects" or
similar expressions, involve known and unknown risks and
uncertainties. Although the Company believes that the expectations
reflected in these forward-looking statements are reasonable, they
do involve assumptions, risks and uncertainties, and these
expectations may prove to be incorrect. Investors should not place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The Company's actual
results could differ materially from those anticipated in these
forward-looking statements as a result of a variety of factors,
including those discussed in the Company's periodic reports that
are filed with the Securities and Exchange Commission and available
on its website ( http://www.sec.gov/ ). All forward-looking
statements attributable to the Company or persons acting on its
behalf are expressly qualified in their entirety by these factors.
Other than as required under the securities laws, the Company does
not assume a duty to update these forward-looking statements. For
more information, please contact: Company Contact: China Biologic
Products, Inc. Mr. Y. Tristan Kuo Chief Financial Officer Tel:
+86-538-6202206 Email: Web: http://www.chinabiologic.com/ Investor
Relations Contact: CCG Investor Relations Mr. Crocker Coulson,
President Tel: +1-646-213-1915 (NY office) Email: Mr. Gary Chin
Tel: +1-646-213-1909 Web: http://www.ccgirasia.com/ DATASOURCE:
China Biologic Products, Inc. CONTACT: Mr. Y. Tristan Kuo, Chief
Financial Officer of China Biologic Products, Inc.,
+86-538-6202-206, ; or Investor Relations Contact - Mr. Crocker
Coulson, President, +1-646-213-1915 (NY office), , or Mr. Gary
Chin, +1-646-213-1909, both of CCG Investor Relations Web site:
http://www.chinabiologic.com/
Copyright